Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
Our preclinical study confirmed that copper accumulation can lead to radioresistance in vitro
and in vivo, and reducing the concentration of copper with copper chelator help to overcome
radioresistance. Therefore, the investigators plan to carry out a prospective interventional
phase II clinical trial to explore the safety and efficacy of penicillamine (a common copper
chelator) as a radiosensitizer in the treatment of recurrent head and neck cancer.